In September 2020, ICER published the white paper: “Cornerstones of ‘Fair’ Drug Coverage: Appropriate Cost-Sharing and Utilization Management Policies for Pharmaceuticals.” This paper analyzes the ethical and practical dimensions of insurance coverage policy, while presenting a corresponding set of criteria that will support a more transparent discussion among all health care stakeholders about whether specific policies are delivering “fair” patient access to prescription drugs.
Building on the criteria discussed within that paper, ICER convened a multi-stakeholder working group – comprising more patient community leaders than all other stakeholders combined — to advise ICER as we undertake this new annual initiative to assess Barriers to Fair Access within the prescription drug coverage policies of major US payers.
ICER published its first annual assessment of Barriers to Fair Access on December 1st.
On December 3rd, hosted a public webinar with ICER’s Executive Vice President and Chief Operating Officer Sarah Emond, MPP on the key conclusions of our “Fair Access” initiative.
For questions or additional information, please contact firstname.lastname@example.org.